Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub Saharan Africa and South East Asia

Journal article

Background Aims: The efficacy of NS5A inhibitors against several less common subtypes of hepatitis C virus (HCV) is poorly characterised. Some subtypes including 3b, 3g, 6u and 6v commonly harbour amino acid residues as wild type in NS5A that may confer resistance to direct acting antivirals (DAAs) in other common subtypes. Data from patients also suggest that 1l and 4r with amino acid substitutions at positions 28-31 and 93 in NS5A are relatively resistant to DAA therapy.

Methods: In this study, we tested the efficacy of daclatasvir, elbasvir, ledipasvir, pibrentasvir and velpatasvir against these subtypes using the SGR-JFH1 replicon backbone.

Results: NS5A inhibitors showed different levels of efficacy with only pibrentasvir effective against all tested subtypes. Daclatasvir and ledipasvir were ineffective against 6u and 6v (half maximal effective concentration [EC50] values of 239-321 nM) while 3b and 3g were only susceptible to pibrentasvir. Analysis of effects of individual mutations indicated that Q30R in 1l increased the EC50 of ledipasvir by 18 fold, conferring intermediate resistance, while those of L31M and Y93H in 4r induced increases in EC50s of 2100- and 3575-fold (high level resistance).

Conclusion: The high ledipasvir EC50 values of 1l with the Q30R substitution, 4r L31M and 4r Y93H may explain the treatment failure in patients who were infected with these viruses and treated with ledipasvir + sofosbuvir. This study also shows the ineffectiveness of the first generation NS5A inhibitors against 6u and 6v, and confirms the inherent resistance of 3b and 3g to most NS5A inhibitors. Clinical studies to confirm in vivo sensitivity to NS5A inhibitors are urgently needed so that rational, effective treatment strategies may be developed for unusual subtypes.

Authors: Nguyen, D; Smith, D; Vaughan-Jackson, A; Magri, A; Barnes, E

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Elsevier
• Journal: Journal of Hepatology
• Volume: 73
• Issue: 4
• Pages: 794-799
• Publication date: 2020-05-26
• Acceptance date: 2020-05-12
• DOI: 10.1016/j.jhep.2020.05.029
• EISSN: 1600-0641
• ISSN: 0168-8278
• Pmid: 32470499
• Language: English
• Keywords: FFR; unusual subtypes; NS5A inhibitors; efficacy; HCV